1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Viatris Inc.

Viatris Inc.

VTRS
Viatris Inc.US flagNASDAQ Global Select
17.42
USD
+0.30
- -
20.29BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
18.03
20.66
19.97
21.59
22.28
22.22
22.3
19.87
14.8
13.42
12.85
12.35
12.21
12.72
Basic EPS, GAAP
1.63
2.49
1.8
0.94
1.3
0.69
0.03
-1.11
-1.05
1.71
0.05
-0.53
-3
-0.35
Free Cash Flow per Basic Share
2.89
2.72
4.25
3.99
3.86
4.55
3.12
1.32
2.45
2.41
2.25
1.9
1.9
1.89
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
0.33
0.48
0.48
0.48
0.48
0.48
Book Value per Share
7.92
8.68
19.9
20.77
25.39
23.59
23.02
19.02
16.94
17.36
17.05
15.61
12.78
12.34
Tangible Book Value per Share
-10.54
-8.37
-5.78
-23.47
-23.17
-21.8
-18.13
-15.81
-14.68
-9.85
-7.15
-6.34
-6.21
-5.26
Basic Weighted Avg Shares
383
374
472
513
534
514
516
601
1,209
1,212
1,200
1,193
1,171
1,159
Sales/Revenue/Turnover
6,909
7,720
9,429
11,077
11,908
11,434
11,500
11,946
17,886
16,263
15,427
14,739
14,300
14,737
Operating Margin (%)
16.22
17.11
14.46
12.38
11.96
7.49
6.04
-0.51
2.04
10.18
10.13
4.82
1.77
0.89
Depreciation Expense
516
567
1,032
1,523
1,806
2,110
2,019
2,216
4,506
3,028
2,740
2,893
2,798
2,804
Net Income, GAAP
624
929
848
480
696
352
17
-670
-1,269
2,079
55
-634
-3,515
-411
Effective Tax Rate (%)
16.16
4.25
7.4
- -
22.92
- -
89.12
- -
- -
26.11
73.04
- -
- -
- -
Profit Margin (%)
9.03
12.04
8.99
4.33
5.84
3.08
0.15
-5.61
-7.1
12.78
0.35
-4.3
-24.58
-2.79
Working Capital
1,507
1,137
2,350
2,482
828
1,780
1,188
2,305
1,018
3,889
5,199
3,741
2,695
3,710
LT Debt
7,586
5,700
6,296
15,203
12,865
13,161
11,390
22,659
19,918
18,197
16,354
14,218
12,659
11,772
Total Equity
2,960
3,276
9,766
11,118
13,308
12,167
11,884
22,954
20,493
21,072
20,467
18,636
14,711
14,260
Return on Invested Capital (%)
9.32
11
9.24
- -
4.32
- -
0.3
- -
- -
2.89
1.06
- -
- -
- -
Return on Capital (%)
8.8
10.93
8.03
- -
4.05
- -
0.29
- -
- -
5.96
0.53
- -
- -
- -
Return on Common Equity (%)
19.86
29.99
13.02
4.6
5.7
2.77
0.14
-3.85
-5.84
10
0.26
-3.24
-21.08
-2.75

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,039
2,029
1,854
LT Borrowings
12,481
12,414
11,612
LT Finance Leases
178
167
160
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,151
1,164
1,155
Market Capitalization
14,333
15,731
18,345

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
9,789
10,917
10,056
Cash, Cash Equivalents & STI
1,513
2,400
1,510
Accounts Receivable, Net
2,578
2,577
2,581
Inventories
3,999
3,927
3,933
Total Current Liabilities
7,094
6,810
6,346
Payables & Accruals
4,065
3,843
3,626
ST Debt
2,039
2,029
1,854
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.5%
-8.15%
-21.06%
Free Cash Flow
18.11%
49.37%
-1.77%
Net Income, GAAP
-530.73%
-215.38%
454.23%
Sales/Revenue/Turnover
5.35%
5.61%
-2.98%
Total Cash Common Dividend
- -
- -
-2.37%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,663
3,797
3,751
3,528
14,739
2025
3,254
3,582
3,760
3,704
14,300
2026
3,517
3,757
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
-0.27
0.08
-0.43
-0.53
2025
-2.55
- -
-0.11
-0.3
-3
2026
0.15
-0.1
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.12
0.12
0.12
0.48
2025
0.12
0.12
0.12
0.12
0.48
2026
0.12
0.12
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Scott Andrew Smith
Full Time Employees
30,000
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Robert J. Coury Global Center Canonsburg PA United States of America 15317
IPO Date
Mar 17, 1980
CIK
0001792044
Website
viatris.com
Similar Companies
Paion AG (PAIOF)
EVIO, Inc. (EVIO)
HEXO Corp. (HEXO.TO)
Neuland Laboratories Limited (NEULANDLAB.BO)
Laboratorios Richmond S.A.C.I.F. (RICH.BA)
Silver Spike Investment Corp. (SSIC)
Business
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company that develops, manufactures and markets a broad portfolio of branded and generic pharmaceuticals, biosimilars and complex generics; key brands include Lipitor, Norvasc, Viagra, Lyrica, Xanax, Creon, Celebrex, Effexor, Zoloft and EpiPen auto-injectors; generics and branded generics span therapeutic areas such as cardiovascular, central nervous system, infectious diseases, oncology, immunology, women's health, diabetes, gastroenterology, respiratory, allergy and dermatology; additional offerings encompass complex generics like Breyna (generic Symbicort), recent launches including Iron Sucrose Injection USP for iron deficiency anemia and Ryzumvi (phentolamine ophthalmic solution) for mydriasis; the company operates in developed markets, emerging markets, JANZ (Japan, Australia, New Zealand) and Greater China, supplying medicines to approximately 1 billion patients annually through global manufacturing and supply chain infrastructure. Headquartered in Canonsburg, Pennsylvania, Viatris was formed in 2020 through the merger of Mylan N.V. and Pfizer's Upjohn division. Recent developments include the completion of the acquisition of Aculys Pharma Inc. in 2025, securing exclusive rights to pitolisant for narcolepsy and obstructive sleep apnea in Japan and Spydia Nasal Spray for status epilepticus in Japan and certain Asia-Pacific markets; submission of a New Drug Application to the U.S. FDA for a low-dose estrogen weekly patch, with anticipated approval by mid-2026; prior divestitures in 2023-2024 of its OTC business to Cooper Consumer Health, women's healthcare business and India API operations for approximately $3.6 billion; an ongoing enterprise-wide strategic review initiated in February 2025 to identify operating efficiencies in commercial, R&D, supply chain and corporate functions; and a December 2024 U.S. FDA warning letter and import alert on its Indore, India facility impacting 11 products, prompting corrective actions.

Company News

Company News APIChatGPT

  • benzinga.com

    Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

  • prnewswire.com

    Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome

  • seekingalpha.com

    Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive

  • zacks.com

    Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?

  • proactiveinvestors.co.uk

    Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris

  • zacks.com

    3 Generic Drug Stocks to Watch Amid Improving Industry Trends

  • zacks.com

    Here's Why Viatris (VTRS) is a Strong Value Stock

  • seekingalpha.com

    Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript

  • gurufocus.com

    Viatris Inc (VTRS) Shares Fall 7.6% -- GF Value Says Still Overvalued

  • benzinga.com

    Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook

  • zacks.com

    VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump

  • zacks.com

    Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics

  • zacks.com

    Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates

  • gurufocus.com

    Is Viatris Inc (VTRS) Worth the Investment After Q2 Earnings? EPS at $0.69, Revenue of $3,756.8 Million with GF Score of 58/100

  • prnewswire.com

    Viatris Reports Second-Quarter 2026 Financial Results

  • zacks.com

    Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

  • zacks.com

    Viatris Gears Up to Report Q2 Earnings: What's in the Cards?

  • prnewswire.com

    Viatris Announces Quarterly Dividend

  • zacks.com

    Viatris (VTRS) Q2 Earnings Preview: What's in the Cards?

  • prnewswire.com

    Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch